Up-regulation of activation-induced cytidine deaminase causes genetic aberrations at the CDKN2b-CDKN2a in gastric cancer.

Author(s)
Matsumoto, Yuko; Marusawa, Hiroyuki; Kinoshita, Kazuo; Niwa, Yoko; Sakai, Yoshiharu; Chiba, Tsutomu

Citation

Issue Date
2010-12

URL
http://hdl.handle.net/2433/134556

© 2010 AGA Institute Published by Elsevier Inc.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.

Type
Journal Article

Textversion
author

Kyoto University
Upregulation of activation-induced cytidine deaminase causes genetic aberrations at the CDKN2b-CDKN2a in gastric cancer

Yuko Matsumoto¹, Hiroyuki Marusawa¹, Kazuo Kinoshita², Yoko Niwa², Yoshiharu Sakai³, and Tsutomu Chiba¹

¹Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
²Evolutionary Medicine, Shiga Medical Center Research Institute, Shiga, Japan.
³Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Short Title: Aberration of CDKN2b-CDKN2a locus by AID activity

Abbreviations used: AID, activation-induced cytidine deaminase; BCL6, B-cell CLL/lymphoma 6; CDKN2A, cyclin-dependent kinase inhibitor 2A; CDKN2B, cyclin-dependent kinase inhibitor 2B; CGH, comparative genomic hybridization; CSR, class switch recombination; DSBs, double-strand breaks; LOH, loss of heterozygosity.

Address correspondence to: Hiroyuki Marusawa, M.D, Ph.D,
Department of Gastroenterology and Hepatology,
Graduate School of Medicine, Kyoto University,
54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
E-mail; maru@kuhp.kyoto-u.ac.jp
Phone; +81-75-751-4302
Fax; +81-75-751-4303

Grant support: This study was supported by Grants-in-aid for Scientific Research, 20012029, 20590774, and 21229009 from the Ministry of Education, Culture, Sports, Science, Grant-in-aid for Scientific Research from the Ministry of Health, Labor, and Welfare, Japan, and Takeda Science Foundation.

No conflicts of interest exist.
**Author Contributions:** Y.M. conducted most of the experiments and data analyses, and contributed to manuscript preparations. H.M designed the study, supervised the project, and contributed to manuscript preparations. K.K. performed the FISH analyses, supervised the project, and contributed to manuscript preparations. Y.N. performed the FISH analyses. Y.S. collected human samples. T.C. supervised the project and contributed to manuscript preparations.
Abstract

BACKGROUND & AIMS: The DNA/RNA editing enzyme activation-induced cytidine deaminase (AID) is mutagenic and has been implicated in human tumorigenesis. Helicobacter pylori (H. pylori) infection of gastric epithelial cells leads to aberrant expression of AID and somatic gene mutations. We investigated whether AID induces genetic aberrations at specific chromosomal loci that encode tumor-related proteins in gastric epithelial cells.

METHODS: Human gastric epithelial cell lines that express activated AID and gastric cells from AID transgenic mice were examined for DNA copy-number changes and nucleotide alterations. Copy number aberrations in stomach cells of H. pylori-infected mice and gastric tissues (normal and tumor) from H. pylori-positive patients were also analyzed.

RESULTS: In human gastric cells, aberrant AID activity induced copy number changes at various chromosomal loci. In AID-expressing cells and gastric mucosa of AID transgenic mice, point mutations and reductions in copy number were observed frequently in the tumor suppressor genes CDKN2A and CDKN2B. Oral infection of wild-type mice with H. pylori reduced the copy number of the Cdkn2b-Cdkn2a locus, whereas no such changes were observed in the gastric mucosa of H. pylori-infected AID-deficient mice. In human samples, the relative copy numbers of CDKN2A and CDKN2B were reduced in a subset of gastric cancer tissues, compared with the surrounding non-cancerous region.

CONCLUSIONS: H. pylori infection leads to aberrant expression of AID and might be a mechanism of the accumulation of submicroscopic deletions and somatic mutations in gastric epithelial cells. AID-mediated genotoxic effects appear to occur frequently at the the CDKN2b-CDKN2a locus and contribute to malignant transformation of the gastric mucosa.

KEY WORDS: gastric cancer; activation-induced cytidine deaminase; genetic alterations; tumor-related genes
Introduction

Increasing evidence indicates that cancer arises from a stepwise accumulation of genetic changes and that the incipient cancer cells acquire mutant alleles of tumor-suppressor genes and/or proto-oncogenes. Genetic alterations observed in cancers include point mutations, chromosomal number alterations, chromosomal translocations, and gene deletions or amplifications. A number of human cancers have deletions and/or point mutations at specific gene loci, causing the putative inactivation of tumor-suppressor genes. Thus, elucidation of the molecular mechanisms underlying the genetic alterations that occur at the loci encoding tumor-suppressor proteins is important to gain a better understanding of tumorigenesis.

A novel mechanism of genetic alterations, i.e., DNA/RNA editing by members of cytidine deaminases, was recently reported. Among the 11 human cytidine deaminases identified, activation-induced cytidine deaminase (AID) is the only molecule that exerts genetic effects on human DNA sequences under physiologic conditions. AID is an essential enzyme for somatic hypermutation, class switch recombination (CSR), and gene conversion, all of which are crucial steps to achieve the diversification of the immunoglobulin (Ig) genes in activated B lymphocytes. In sharp contrast to the physiologic role of AID in the editing of the Ig genes, we recently demonstrated a pathologic role of AID linking the accumulation of nucleotide alterations in tumor-related genes and human cancer development. Indeed, aberrant expression of AID is induced in response to pro-inflammatory cytokine stimulation in gastric epithelial cells, colon epithelial cells, biliary ductal cells, and hepatocytes and leads to the accumulation of somatic mutations in various tumor-related genes in vitro. Moreover, we showed that infection with Helicobacter pylori, a class one carcinogen for gastric cancer, induces aberrant AID expression in gastric epithelial cells, resulting in the accumulation of TP53 tumor suppressor gene mutations. Consistent with these in vitro findings, a mouse model with continuous and
ubiquitous expression of AID develops cancers in several epithelial organs, including stomach, liver, and lung, via the accumulation of somatic mutations. These findings elucidated a novel molecular mechanism linking inflammation, genetic mutations, and cancer development.

Because AID can trigger a CSR of the Ig gene, it is reasonable to assume that AID can also mediate chromosomal aberrations by triggering double-strand DNA breaks (DSBs) in lymphoid cells, in addition to somatic point mutations. Indeed, recent studies revealed that AID is required for the generation or accumulation of chromosomal translocations during lymphoma development. For example, translocations between c-myc and the IgH locus (Igh) are induced in primary B cells within hours of AID expression, while c-myc-Igh translocations are absent in AID-deficient mice. These findings prompted us to speculate that aberrant expression of AID in epithelial cells might cause not only somatic point mutations but also chromosomal alterations, both of which would play critical roles in the activation and/or inactivation of tumor-related genes. In this study, therefore, we investigated whether the genotoxic activity of AID could underlie the emergence of genetic aberrations at specific chromosomal loci encoding tumor-related proteins in human gastric epithelial cells and thus contribute to the development of gastric cancers.
Materials and Methods

Mice

The generation of transgenic (Tg) mice with constitutive and ubiquitous AID expression and AID-deficient mice was described previously 15, 24. Wild-type (WT) C57BL/6J mice were purchased from Japan SLC, INC. (Shizuoka, Japan). For infection, mice were challenged with 1.5 x 10^7 cfu CagPAI-positive (TN2GF4) *H. pylori* as described previously 25-27. All experiments involving mice conform to the relevant regulatory standards and were reviewed and approved by Kyoto University School of Medicine Institutional Animal Care and Use Committee.

Cell culture and transfection

AGS human gastric epithelial cells and stable transfection of AID-expressing vector into AGS cells was described previously 13.

Genomic PCR, RT-PCR, and quantitative real-time genomic and RT-PCR

The oligonucleotide primers used are shown in Supplementary Table 1. Quantification of gene expression or gene copy numbers was performed by quantitative real-time RT-PCR or genomic PCR using a Light Cycler 480 and Fast Start Universal Probe or SYBR Master (Roche, Mannheim, Germany)9. To assess the quantity of isolated DNA, target DNAs were normalized to the DNA levels of the housekeeping reference gene human *ACTB* or mouse *Actb*. For simplicity, the ratios are represented as relative values, target gene/human *ACTB* or mouse *Actb*.

Comparative genomic hybridization (CGH) microarray analysis

Genomic analyses were performed on Human 44K Agilent arrays CGH (Agilent Technologies, Santa Clara, CA) according to the manufacturer's protocol. DNA extracted from AID-overexpressing AGS cells and reference DNA were both labeled by random priming with Cy3-dCTP and Cy5-dCTP for dye-swap experimental design. Arrays were scanned on an Agilent microarray scanner. Data were extracted and flagged with the Feature Extraction
software. Agilent CGH Analytics software was used to identify regions of copy number alteration.

Fluorescence in situ hybridization (FISH) analysis

DNA probes specific to CDKN2b–CDKN2a locus and ELAVL2 gene were amplified using the primers shown in Supplementary Table 1. These probes were labeled by nick-translation with either SpectrumGreen- or SpectrumOrange-labeled dUTP and hybridized to chromosomes of AGS cells expressing AID for 21 days. Images were taken with the fluorescence microscope MD5000B (Leica, Wetzlar, Germany).

DNA polymorphism analysis

The DNA polymorphism analyses of restriction fragment length polymorphisms were performed to detect loss of heterozygosity (LOH). PCR was performed using the primer sets shown in Supplementary Table 1, and PCR products were digested with Dde I (for human CDKN2A) or Psp 1406 I (for human CDKN2B).

Southern blot analysis

Southern blot analysis of the PCR products was performed using AlkPhos Direct Labelling Reagents (GE Healthcare, Buckinghamshire, UK), with DNA probes labeled using alkaline phosphatase, according to the manufacturer's protocol. The primer sets used are shown in Supplementary Table 1.

Subcloning and sequencing of tumor-related genes

The oligonucleotide primers used are shown in Supplementary Table 1. Amplification of the target sequences was performed using high-fidelity Phusion Taq polymerase (Finnzymes, Espoo, Finland), and the products were subcloned into a pcDNA3 vector (Invitrogen, Carlsbad, CA). The resulting plasmids were subjected to sequence analysis.¹¹
Patients

The study group comprised 28 patients who had undergone potentially curative resection of primary gastric cancer at Kyoto University Hospital from 2006 to 2007. Written informed consent for the use of the resected tissues was obtained from all patients in accordance with the Declaration of Helsinki, and the Kyoto University Graduate School and Faculty of Medicine Ethics Committee approved the study.

Statistics

Statistical significance ($P < 0.05$) was evaluated using the $\chi^2$ test for sequence and FISH analyses, and the Mann–Whitney U-test for quantitative real-time PCR analysis.
Results

AID expression induces chromosomal aberrations in gastric epithelial cells.

To view the overall landscape of the genetic alterations caused by AID activation in human gastric epithelial cells, we used a system that allows for conditional AID activation by constructing a stable transfectant of AID fused with the hormone-binding domain of the human estrogen receptor in the human gastric epithelial cell line AGS (Supplementary Figure 1). We then conditionally activated AID in the cells by introducing an estrogen analogue, 4-hydroxytamoxifen, followed by CGH analyses performed on DNA samples extracted from the cells with or without AID activation. Copy number changes emerged in a number of submicroscopic areas in almost all chromosomes of the cells with AID activation compared with the control cells (Supplementary Figure 2). Most of the changes observed in the AID-expressing cells were submicroscopic deletions represented by copy number losses of various chromosomal loci, whereas large-scale deletions or changes in chromosomal number, such as monosomy, were not apparent in the cells with AID expression. In contrast, a submicroscopic copy number gain was observed in a few chromosomal loci on 3p, 10q, and 19p in AID-expressing cells (Supplementary Figure 2). Analysis of the time-course changes in the copy numbers revealed that the number of submicroscopic chromosomal deletions increased depending on the duration of AID activation in gastric cells (Figure 1A and Supplementary Table 2). These findings suggested that AID expression caused the copy number changes, mainly by inducing submicroscopic chromosomal deletions, in gastric epithelial cells.

AID induces reductions of the CDKN2A and CDKN2B copy numbers in gastric epithelial cells.
Repeated CGH analyses on AGS cells showed that deletions at two specific loci, 9p21 and 3q27, commonly occurred after 1-week and 3-week AID activation, though there were many deleted regions observed. Notably, these chromosomal regions harbored the tumor-suppressor genes cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase inhibitor 2B (CDKN2B) at 9p21, and B-cell CLL/lymphoma 6 (BCL6) at 3q27 (Figure 1A). It has been well recognized that CDKN2A and CDKN2B play crucial roles as tumor-suppressor genes in the development of various human tumors. Therefore, we further examined whether AID expression caused the deletion of the CDKN2b-CDKN2a locus at 9p21 using fluorescence in situ hybridization (FISH) analyses with the probes specific for CDKN2b-CDKN2a locus and control ELAVL2 gene. We found that significantly more deletions of CDKA2b-CDKN2a locus were present in human gastric cells with AID activation than those in the control cells (27.6% and 6.9%, respectively; \( P < 0.001 \); Figure 1B and Table 1). In contrast, there was no significant difference in the frequency of deleted signals for ELAVL2 gene between AID-expressing cells and cells without AID activation (11.9% and 11.2%, respectively; Table 1). These results suggest that AID preferentially induces submicroscopic deletions of CDKN2A and CDKN2B genes in gastric epithelial cells.

Next, we analyzed the gastric mucosa of AID Tg mice, which develop various tumors, including gastric cancer, in association with the accumulation of somatic mutations. We examined the relative copy number ratio of Cdkn2a and Cdkn2b at chromosome 4, and Bcl6 at chromosome 16, in non-cancerous gastric mucosa (NC) as well as in the gastric cancer tissue (GC) of AID Tg mice (Figure 2A). As a reference, we selected several genes, such as Acot7 at chromosome 4 and Actb at chromosome 5, that were located at stable chromosomal sites in the AID-expressing cells in vitro. The relative copy number ratios of Cdkn2a and Cdkn2b were significantly lower in gastric epithelial cells of AID Tg mice compared with those of the WT
mouse ($P < 0.05$; Figure 2B and C). Moreover, the gastric cancer tissues had substantially reduced amounts of Cdkn2a and Cdkn2b compared with the non-cancerous gastric mucosa in the AID Tg mice (Figure 2B and C). All of the AID Tg mice also had significantly reduced copy number levels of Bcl6 in the gastric mucosa compared with the WT mouse ($P < 0.01$; Figure 2D). In contrast, there was little difference in the copy numbers of the Acot7 gene between the gastric mucosa of the WT and AID Tg mice (Figure 2E). Southern blotting analyses revealed that signals derived from the Cdkn2a gene in the gastric mucosa of the AID Tg mice were substantially reduced compared with that in the WT mouse (Figure 2F). These findings together suggested that constitutive expression of AID in normal gastric epithelial cells resulted in submicroscopic Cdkn2a and Cdkn2b gene defects at high frequency in vivo.

**AID expression in gastric epithelial cells caused somatic mutations in the CDKN2A and CDKN2B genes.**

To further determine if the CDKN2A and CDKN2B genes are preferential targets of AID-mediated genotoxic effects, we examined whether somatic mutations are induced by AID activation in CDKN2A and CDKN2B genes of gastric cells in vitro and in vivo. In vitro, control AGS cells without AID activation contained only a single or two nucleotide alterations of the CDKN2A or CDKN2B gene sequences (Table 2). In contrast, gastric cells with AID activation had significantly higher frequencies of nucleotide alterations in the CDKN2A and CDKN2B genes than those in control cells ($P < 0.01$; Table 2). Of the 19 mutations in CDKN2A of AID-activated AGS cells, 1 was a nonsynonymous mutation and another was a frameshift mutation resulting in loss of function. Three of 11 mutations in CDKN2B of AID-activated AGS cells were nonsynonymous mutations. Substantially higher mutation frequency was also observed in the BCL6 gene in the cells with AID activation than that in control cells (Table 2).
Similar findings were obtained by analyses of the gastric mucosa from AID Tg mice. We detected only a single or two nucleotide alterations in either of the Cdkn2a or Cdkn2b genes in the gastric mucosa of WT mice (Table 3). In contrast, a number of somatic mutations were induced in the Cdkn2a and Cdkn2b genes in the gastric mucosa of AID Tg mice (Table 3). Significantly higher frequencies of nucleotide alterations in Cdkn2a and Cdkn2b genes were detected in non-cancerous tissue as well as in gastric cancer in AID Tg mice than in control gastric tissue from WT mice (P < 0.01; Table 3). Interestingly, 6 of 11 (55%) nucleotide changes in non-cancerous tissue and 10 of 14 (71%) in cancer tissue occurring in the coding sequences of the Cdkn2a gene were nonsynonymous mutations resulting in amino acid substitutions, and 1 of 11 (9%) nucleotide alteration in non-cancerous tissue was a nonsense mutation resulting in a stop codon. Furthermore, 2 of 10 (20%) nucleotide changes in non-cancerous tissue and 1 of 14 (7%) in cancer tissue in the coding sequences of the Cdkn2b gene were also nonsynonymous mutations. In contrast, there was no difference in the mutation frequencies of the Bcl6 gene between AID Tg and WT mice.

Taken together, these findings suggested that AID-triggered genotoxic effects were preferentially aimed at the CDKN2A and CDKN2B genes, and induced both submicroscopic deletions and nucleotide alterations of these tumor-suppressor genes in gastric epithelial cells.

**H. pylori infection triggered the loss of the Cdkn2a and Cdkn2b genes in gastric epithelial cells.**

We previously demonstrated that *H. pylori* infection induces aberrant expression of endogenous AID in gastric epithelial cells. To determine whether persistent *H. pylori* infection leads to changes in the Cdkn2a/Cdkn2b gene loci via AID expression, we orally infected WT C57BL/6J mice or AID-deficient mice with a cagPAI-positive pathogenic strain of *H. pylori*, followed by analysis of the gastric mucosa for nucleotide alterations.
TN2GF4 (Supplementary Figure 3), and determined the relative copy number ratios of the Cdkn2a and Cdkn2b genes in the gastric mucosa. We first confirmed that oral infection of H. pylori in WT mice upregulated AID expression in the gastric mucosa (Figure 3A, upper panel), whereas endogenous AID expression was undetectable in uninfected mouse stomach (Figure 3A, upper panel) or in AID-deficient mice with H. pylori infection (Figure 3D, upper panel). Interestingly, relative copy number ratios of Cdkn2a were significantly lower in most of the stomachs of WT mice infected with H. pylori, compared with uninfected mice (P < 0.05; Figure 3B). Similarly, there was a significant reduction in the copy number ratio of the Cdkn2b gene in the gastric mucosa in association with H. pylori infection, compared with the mice without H. pylori infection (P < 0.05; Figure 3C). In contrast, there was no change in the relative copy number ratio of the Cdkn2a and Cdkn2b genes in the stomach of AID-deficient mice with H. pylori infection (Figure 3E and F). These observations suggested that H. pylori infection triggered the submicroscopic deletion of Cdkn2a and Cdkn2b genes via endogenous AID expression in the gastric mucosa.

Although the CGH array analyses on the gastric mucosa of the H. pylori-infected mouse detected a number of submicroscopic deletions in various chromosomal loci (Supplementary Figure 4), we did not detect a reduction in the copy number of the known tumor-related genes that are commonly reduced in the H. pylori-infected mouse stomach and the cultured human gastric cells with AID expression.

**Genetic alterations of CDKN2A and CDKN2B in H. pylori-positive human gastric cancers.**

Previous studies revealed that epigenetic changes in the promoter region contribute to the downregulation of CDKN2A or CDKN2B gene expression, leading to inactivation of these tumor-suppressor genes in various human cancers. In contrast, little is known about the
genetic alterations in \textit{CDKN2A} and \textit{CDKN2B} genes during human gastric cancer development. Thus, we analyzed the relative copy number ratios of \textit{CDKN2A} and \textit{CDKN2B} in \textit{H. pylori}-positive human gastric cancer clinical specimens. The relative copy number ratio of the \textit{CDKN2A} or \textit{CDKN2B} genes was reduced to less than half in 10 of 28 (36\%) tumors compared with those of the surrounding non-tumorous gastric mucosa of patients with gastric cancers, and the copy number of the \textit{CDKN2A} or \textit{CDKN2B} genes was significantly lower in tumorous tissue than in surrounding non-tumorous gastric mucosa among these cases \((P < 0.05; \text{Figure 4A and B})\). Real-time RT-PCR analyses revealed that the expression levels of both \textit{CDKN2A} and \textit{CDKN2B} transcripts were significantly lower in tumorous tissues than in non-tumorous gastric mucosa in the clinical specimens with \textit{CDKN2A} and \textit{CDKN2B} gene copy number reductions \((P < 0.05; \text{Supplementary Figure 5A and B})\). Southern blot analyses revealed that genetic signals derived from the \textit{CDKN2A} gene in cancer tissues were substantially smaller than those in the surrounding non-cancerous gastric mucosa of the 10 patients with the reduced levels of \textit{CDKN2A} and \textit{CDKN2B} copy numbers (Figure 4C, upper panel). In addition, DNA polymorphism analyses showed that LOH in \textit{CDKN2A} or \textit{CDKN2B} gene was detectable in 4 of 10 gastric cancer tissue specimens examined (Figure 4D and E). Taken together, these findings suggested that submicroscopic deletions of the \textit{CDKN2b} and \textit{CDKN2a} loci were present in a subset of human gastric cancer tissues.
**Discussion**

Various genetic alterations contribute to the inactivation of tumor-suppressor genes during cancer development. We previously demonstrated that *H. pylori* infection and the resultant inflammatory response ectopically induce AID expression in human gastric epithelial cells, leading to the generation of somatic mutations in various tumor-related genes such as *TP53*. On the other hand, deletion of specific chromosomal loci is another major genetic event that inactivates tumor-suppressor genes. The molecular processes underlying chromosomal deletions, including DSBs and subsequent joining of DNA ends during tumorigenesis, however, remain unclear. In the present study, we demonstrated that aberrant AID expression caused chromosomal alterations, mainly submicroscopic deletions, at various genetic loci in gastric epithelial cells.

The molecular mechanism underlying AID-dependent chromosomal deletions in gastric epithelial cells remains unknown. In the case of the CSR of the *Ig* gene, which is achieved via the generation of DSBs, a nick or gap in the DNA sequence is generated during the repair process of AID-initiated C deamination at the preferred sites of the *Ig* gene. Consequently, AID could potentially induce a staggered DSB by generating closely positioned single-strand nicks on opposite DNA strands in certain hotspots of the IgH switch regions. DNA lesions intermediate to CSR are occasionally misrepaired, leading to chromosomal DSBs, translocations, and deletions in B lymphocytes. A well-studied case involves the t(8;14)(q24;q32) chromosomal translocations that juxtapose the *Ig* heavy chain (IgH) to the proto-oncogene *c-Myc* in human Burkitt’s lymphomas. Indeed, several studies have demonstrated the generation of *c-myc-Igh* translocations in the presence of AID in mouse models of developing lymphomas. Thus, the catalytic activity of AID that is capable of initiating DSBs supports the idea that aberrant AID expression in gastric epithelial cells leads to chromosomal aberrations, resulting in
submicroscopic deletions at various chromosomal loci.

The findings of the present study demonstrated that aberrant AID expression preferentially caused chromosomal aberrations at the CDKN2b-CDKN2a locus in gastric epithelial cells. Chromosomal region 9p21 contains the CDKN2b-CDKN2a locus, which encodes three tumor suppressor proteins, p16\(^{\text{INK4a}}\), p15\(^{\text{INK4b}}\), and p14\(^{\text{ARF}}\). p16\(^{\text{INK4a}}\) and p14\(^{\text{ARF}}\) are potent tumor suppressors that regulate the activities of the retinoblastoma protein and the TP53 transcription factor. Several mechanisms are involved in the inactivation of p16\(^{\text{INK4a}}\) and p14\(^{\text{ARF}}\), including chromosomal deletion, somatic mutation, and methylation of CpG islands extending from the promoter region to the first exon. The deletion at chromosome 9p21 in humans, which removes the CDKN2A tumor-suppressor gene, is a genetic alteration frequently observed in several human cancers, prompting speculation that biochemical pathways regulated by these proteins must be disabled for normal cells to be transformed into tumor cells. Consistent with these findings, we previously demonstrated that AID expression in biliary cells induces somatic mutations in the promoter region of the CDKN2A gene. Thus, the CDKN2b-CDKN2a locus might be a common target for AID-mediated genotoxic effects in both gastric and biliary epithelial cells.

In sharp contrast to the CDKN2b-CDKN2a locus, few of the other genes examined exhibited a common susceptibility to AID-mediated genotoxic effects in human and mouse gastric epithelial cells. It should be noted that the human CDKN2b-CDKN2a locus is located on chromosome band 9p21, while the cognate locus of the mouse genes is present on chromosome 4. The reason for the selective AID attack of the CDKN2b-CDKN2a locus in both humans and mice irrespective of the chromosomal region, is not clear. Consistent with the hypothesis that the CDKN2A deletion is triggered by AID activity, previous structural analyses of breakpoints for CDKN2A deletions in human cancers revealed that DSBs triggering deletions in leukemia cells
are formed at a few defined sites by the illegitimate action of the RAG protein complex, while DSBs in solid tumors are formed at nonspecific sites in or near the CDKN2a locus by undefined factors. It was recently demonstrated that AID expression is required to introduce DNA single-strand breaks into both rearranged IgH variable-region genes and the CDKN2B gene in leukemia cells, and frequent deletion of CDKN2A and CDKN2B was also reported in the AID-positive lymphoid blast crisis leukemia cells. In support of these findings, we confirmed that the upstream sequences of the CDKN2b-CDKN2a locus carries E box motifs (CAGGTG), which are tightly associated with AID hypermutation activity at both Ig and non-Ig genes, at very high density (11 motifs within 10 kbp sequences). Together these findings suggest that there are AID-preferential motifs in the sequences around the CDKN2a locus in both human and mouse, and thus the genotoxic activity of AID triggers preferential chromosomal deletions as well as somatic point mutations in the CDKN2b-CDKN2a locus.

A number of tumor suppressor genes exhibit epigenetic changes with resulting gene silencing in cancers and it is well recognized that the CDKN2A gene is frequently inactivated by aberrant methylation. In contrast, little is known about the genetic changes in the CDKN2A and CDKN2B genes in human gastric cancers. Here we demonstrated that copy number losses of the CDKN2b-CDKN2a locus were present in a subset of human gastric cancer tissues. We also showed that H. pylori infection triggered a reduction in the copy numbers of the Cdkn2a and Cdkn2b genes in the gastric mucosa of WT mice, and strikingly, the alterations of the Cdkn2b-Cdkn2a gene loci induced by H. pylori infection were not observed in AID-deficient mice, indicating an indispensable role of AID in H. pylori-induced genetic alterations of the CDKN2b-CDKN2a loci. Because a large population of gastric cancer patients are commonly infected with H. pylori and H. pylori potently enhances AID expression in gastric epithelial cells, the present data strongly suggest that H. pylori infection triggers inactivation of the CDKN2A and
CDKN2B genes through AID-mediated genetic aberrations, contributing to the emergence of gastric cancers.

In conclusion, we demonstrated that aberrant AID expression in gastric epithelial cells resulted in the accumulation of submicroscopic deletions in various chromosomal loci. The findings that AID preferentially targeted the tumor-suppressor CDKN2b-CDKN2a locus in gastric epithelial cells suggest the significance of AID production in gastric cancer development. Further analyses are necessary to determine the precise multistep process of genetic alterations in human gastric mucosa in association with H.pylori-mediated AID expression.
Figure legends

Figure 1

Copy number analyses of CDKN2A and CDKN2B genes in AGS cells with or without AID activation.

(A) Copy number profiles on chromosomes 3 and 9 of AGS cells with AID activation for 1 or 3 weeks, using CGH analyses, are shown. The BCL6 gene is located on chromosome 3, and the CDKN2A and CDKN2B genes are located on chromosome 9. Red and green dots represent copy number amplification and reduction, respectively. (B) Dual-color FISH analyses for AID-expressing AGS cells. Representative images for the CDKN2b-CDKN2a locus (green signals) and ELAVL2 gene (red signals) in cells with AID activation for 3 weeks. Chromosomes with both CDKN2b-CDKN2a locus and ELAVL2 gene had green and red signals (CDKN2b-2a(+)/ELAVL2(+) left panels). Chromosomes without CDKN2b-CDKN2a signals had only red signals (CDKN2b-2a(-)/ELAVL2(+) right panels).

Figure 2

Copy number analyses of Cdkn2a, Cdkn2b, and Bcl6 genes extracted from gastric epithelial cells of 1-year-old WT and AID Tg mice.

(A) Microscopic images (hematoxylin and eosin stain) of a representative gastric cancer developed in a 53-week-old AID Tg mouse (original magnification ×40, upper panel, and original magnification ×200, lower panel). Scale bars are 1 mm (upper panel) and 200 µm (lower panel). (B, C, D and E) Relative copy number ratio of the Cdkn2a (B), Cdkn2b (C), Bcl6 (D), and Acot7 (E) genes in the gastric epithelium of the WT and three AID Tg mice, one of which developed gastric cancer. Normal gastric mucosa of the WT mouse (WT), non-cancerous mucosa of three AID Tg mice (NC), and gastric cancer of the AID Tg mouse (GC) were examined. *, P<0.05. **, P<0.01. (F) Southern blot analysis of the Cdkn2a gene in the gastric...
epithelium of the WT and three AID Tg (Tg#1-3) mice (upper panel) and that of the control Actb gene (lower panel).

Figure 3

Copy number analyses of Cdkn2a and Cdkn2b genes extracted from gastric epithelial cells of WT mice with 2-year H. pylori infection.

(A and D) AID expression analyses using PCR were performed in gastric epithelial cells with H. pylori infection of WT (A; upper panel) or AID-deficient mice (D; upper panel). Control Actb expression analyses are shown in lower panels of Figures 4A and D. (B, C, E and F) Relative copy number ratio of the Cdkn2a or Cdkn2b genes in gastric epithelium with or without H. pylori infection in WT or AID-deficient mice. The data shown represent mean amounts of the Cdkn2a or Cdkn2b genes in three WT mice (B and C) or three AID-deficient mice (E and F) with H. pylori infection (HP[+]) or the mice without infection (CTR). *, P<0.05.

Figure 4

Copy number analyses of CDKN2A and CDKN2B genes extracted from stomach of 28 patients with gastric cancer.

(A and B) Relative copy number ratio of the CDKN2A (A) and CDKN2B (B) genes between non-tumor and tumor tissues. (C) Southern blot analysis of the CDKN2A gene in non-tumor and tumor tissues of 4 representative patients (upper panel) and that of the control ACTB gene (lower panel). (D and E) LOH analyses of the CDKN2A (D) and CDKN2B (E) genes in 4 of the 6 informative patients for which DNA polymorphism analyses were performed.
Acknowledgements
We thank Tasuku Honjo (Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan) for his critical reading of the manuscript.
References


Figure 1 Matsumoto et al.

A

Chromosome 3

AID activation for 1 week

BCL6

AID activation for 3 weeks

BCL6

Chromosome 9

DNA amplification

DNA deletion

B

CDKN2b-2a(+) / ELAVL2(+)

CDKN2b-2a(−) / ELAVL2(+)
Figure 2 Matsumoto et al.

A. 

B. 

C. 

D. 

E. 

F. 

Relative gene amounts of Cdkn2a/Actb

WT NC GC Tg

exon1

Relative gene amounts of Cdkn2b/Actb

WT NC GC Tg

exon1

Relative gene amounts of Bcl6/Actb

WT NC GC Tg

Relative gene amounts of Acot7/Actb

WT NC GC Tg

WT Tg#1 Tg#2 NC GC

Tg#3

Cdkn2a (exon1)

Actb

* P < 0.05

* P < 0.01

*p < 0.05

** P < 0.01
Figure 3 Matsumoto et al.

A

$\text{WT mice}$

$\text{AID}$

$\text{Actb}$

$\text{CTR}$

$H. \text{pylori} \, (+)$

B

$\text{WT mice}$

Relative gene amounts of $\text{Cdkn2a}/\text{Actb}$

Relative gene amounts of $\text{Cdkn2b}/\text{Actb}$

C

$\text{WT mice}$

D

$\text{AID-deficient mice}$

$\text{Actb}$

$\text{CTR}$

$H. \text{pylori} \, (+)$

E

$\text{AID-deficient mice}$

Relative gene amounts of $\text{Cdkn2a}/\text{Actb}$

F

$\text{AID-deficient mice}$

Relative gene amounts of $\text{Cdkn2b}/\text{Actb}$

* $P < 0.05$
Figure 4 Matsumoto et al.

A

B

C

Gastric Cancer Tissues

<table>
<thead>
<tr>
<th>Non-tumor</th>
<th>Tumor</th>
<th>Non-tumor</th>
<th>Tumor</th>
<th>Non-tumor</th>
<th>Tumor</th>
<th>Non-tumor</th>
<th>Tumor</th>
</tr>
</thead>
</table>

CDKN2A (exon 2)

ACTB

D

E

Gastric Cancer Tissues

<table>
<thead>
<tr>
<th>uncut</th>
<th>Non-tumor</th>
<th>Tumor</th>
<th>Non-tumor</th>
<th>Tumor</th>
</tr>
</thead>
</table>

CDKN2A

CDKN2B

(bp) 120 75 (bp) 130 65
Table 1. Frequency of chromosomes with deleted signals identified in AID-expressing AGS cells using CDKN2b-CDKN2a/ELAVL2 dual-color FISH analyses.

<table>
<thead>
<tr>
<th>Deleted genes</th>
<th>AID(+)</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequency of the chromosomes without signals</td>
<td>Chromosomes without signals /total chromosomes</td>
</tr>
<tr>
<td>CDKN2b-CDKN2a</td>
<td>27.6% (97/352) *</td>
<td>6.9% (24/347)</td>
</tr>
<tr>
<td>ELAVL2</td>
<td>11.9% (42/352)</td>
<td>11.2% (39/347)</td>
</tr>
</tbody>
</table>

Data represent the frequency of chromosomes with the deletions of targeted genes, and values in parentheses indicate number of chromosomes with deleted genes per number of total chromosomes examined. *, $P < 0.001$, vs. control.
Table 2. Mutation frequency of *CDKN2A*, *CDKN2B* and *BCL6* genes in AGS cells with or without AID activation.

<table>
<thead>
<tr>
<th></th>
<th>AID (+)</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean mutation frequency</td>
<td>Mean mutation frequency</td>
</tr>
<tr>
<td></td>
<td>(Mutated bases / total bases)</td>
<td>(Mutated bases / total bases)</td>
</tr>
<tr>
<td></td>
<td>Mutated clones / total clones</td>
<td>Mutated clones / total clones</td>
</tr>
<tr>
<td><strong>CDKN2A</strong></td>
<td>3.01/10^4 (19/63121) 16/199 *</td>
<td>0.15/10^4 (1/67726) 1/214</td>
</tr>
<tr>
<td><strong>CDKN2B</strong></td>
<td>1.70/10^4 (11/64842) 11/202 *</td>
<td>0.29/10^4 (2/68052) 2/212</td>
</tr>
<tr>
<td><strong>BCL6</strong></td>
<td>0.46/10^4 (5/109203) 5/178</td>
<td>0.082/10^4 (1/121473) 1/198</td>
</tr>
</tbody>
</table>

*CDKN2A*, *CDKN2B* and *BCL6* sequences were amplified from AGS cells with or without AID activation for 21 days, followed by analysis of nucleotide sequences in randomly selected clones. Data represent mean mutation frequency (left), number of mutated bases per number of total base pairs sequenced (middle, in parentheses), and number of mutated clones per number of total clones examined (right). *, P < 0.01, vs. control.
Table 3. Mutation frequency of \textit{Cdkn2a} and \textit{Cdkn2b} genes in normal gastric mucosa of a 1-year-old wild-type mouse (Control) and gastric cancer (GC) and non-cancerous mucosa (NC) of a 1-year-old AID transgenic (Tg) mouse.

<table>
<thead>
<tr>
<th>Gene</th>
<th>AID Tg (GC)</th>
<th>AID Tg (NC)</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean mutation frequency</td>
<td>Mutated clones / total clones</td>
<td>Mutated bases / total bases</td>
</tr>
<tr>
<td>\textit{Cdkn2a}</td>
<td>0.89/10^4 (14/157300)</td>
<td>14/270 *</td>
<td>0.72/10^4 (11/152347)</td>
</tr>
<tr>
<td>\textit{Cdkn2b}</td>
<td>1.55/10^4 (14/90479)</td>
<td>14/106 *</td>
<td>1.05/10^4 (10/95186)</td>
</tr>
</tbody>
</table>

\textit{Cdkn2a} and \textit{Cdkn2b} sequences from mouse gastric mucosa were amplified, followed by analysis of nucleotide sequences in randomly selected clones. Data shown in this table are representative and are derived from one control and one AID Tg mouse that developed gastric cancer, and represent mean mutation frequency (left), number of mutated bases per number of total base pairs sequenced (middle, in parentheses), and number of mutated clones per number of total clones examined (right). *, $P < 0.01$, vs. control.
Supplementary Figure 1 Matsumoto et al. RT-PCR analyses showing the AID expression level in the cell system established by stable transformation of AGS cells with the plasmid encoding the conditionally active form of AID fused with the hormone-binding domain of the human estrogen receptor. The expression of AID (upper panel) and ACTB, encoding β-actin, as an internal control (lower panel), in AGS cells with (+) or without (-) the AID transgene is shown.
Supplementary Figure 2 Matsumoto et al. Chromosomal profiles of human gastric epithelial AGS cells with AID activation for 21 days based on CGH analysis. Ideograms of chromosomes are positioned horizontally and flanked by a copy number plot, which defines 0 as the normal copy number. Red and green dots represent copy number amplification and reduction, respectively.

Chr.  DNA deletion  DNA amplification
Supplementary Figure 3 Matsumoto et al. Histologic analysis of the gastric mucosa of the *H. pylori*-infected WT C57BL/6 (left panel) and AID-deficient (right panel) mice that developed chronic gastritis.
Supplementary Figure 4 Matsumoto et al. Chromosomal profiles of gastric epithelial cells of WT mouse infected with *H. pylori* for 2 years based on CGH analysis. Ideograms of chromosomes are positioned vertically. Green areas represent copy number reduction.
Supplementary Figure 5 Matsumoto et al. CDKN2A and CDKN2B mRNA expression in human gastric cancer and surrounding non-cancerous stomach tissues. Comparison of CDKN2A (A) and CDKN2B (B) transcript expression by quantitative real-time RT-PCR analyses in non-tumor and tumor tissues from the clinical specimens showing copy number reductions of the CDKN2A and CDKN2B genes.
Supplementary Table 1 Matsumoto et al. Oligonucleotide primers used in this study.

<table>
<thead>
<tr>
<th>Primers</th>
<th>Orientation</th>
<th>Sequence (5' – 3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>human CDKN2A</td>
<td>Sense</td>
<td>CACCTCAGAAGTCAGTGGAGT</td>
</tr>
<tr>
<td>human CDKN2B</td>
<td>Sense</td>
<td>AGACTACACAGGATGAGGTT</td>
</tr>
<tr>
<td>human CDKN2A_1</td>
<td>Sense</td>
<td>CCGGAATTCAGCAGCATGGAGGCG</td>
</tr>
<tr>
<td>human CDKN2A_2</td>
<td>Sense</td>
<td>CCGCTCGAGCTGAGCTGGGCT</td>
</tr>
<tr>
<td>human CDKN2B</td>
<td>Sense</td>
<td>CCGGAATTCAGCAGCATGGAGGCG</td>
</tr>
<tr>
<td>human BCL6</td>
<td>Sense</td>
<td>CCGGAATTCAGCAGCATGGAGGCG</td>
</tr>
<tr>
<td>human ACTB</td>
<td>Sense</td>
<td>CCGGAATTCAGCAGCATGGAGGCG</td>
</tr>
<tr>
<td>human ELAVL2_FISH</td>
<td>Sense</td>
<td>TGAGTTAGTGAAGGTAGTGTCT</td>
</tr>
<tr>
<td>mouse Cdkn2a_exon1a</td>
<td>Sense</td>
<td>GAGAGGAGGAGGAGGAGGAGGAG</td>
</tr>
<tr>
<td>mouse Cdkn2a_exon1b</td>
<td>Sense</td>
<td>TGGTCCAGGAGGCCGCAGGCAG</td>
</tr>
<tr>
<td>mouse Cdkn2a_exon2</td>
<td>Sense</td>
<td>TGGTCCAGGAGGCCGCAGGCAG</td>
</tr>
<tr>
<td>mouse Cdkn2b_exon1</td>
<td>Sense</td>
<td>GTGACGAGGAGGCCGCAGGCAG</td>
</tr>
<tr>
<td>mouse Cdkn2b_exon2</td>
<td>Sense</td>
<td>TGGTCCAGGAGGCCGCAGGCAG</td>
</tr>
<tr>
<td>mouse Cdkn2a_1</td>
<td>Sense</td>
<td>CCGGAATTCAGCAGCATGGAGGCG</td>
</tr>
<tr>
<td>mouse Cdkn2a_2</td>
<td>Sense</td>
<td>CCGGAATTCAGCAGCATGGAGGCG</td>
</tr>
<tr>
<td>mouse Cdkn2b</td>
<td>Sense</td>
<td>CCGGAATTCAGCAGCATGGAGGCG</td>
</tr>
<tr>
<td>mouse Cdkn2a_SouthernBlot</td>
<td>Sense</td>
<td>CCGGAATTCAGCAGCATGGAGGCG</td>
</tr>
<tr>
<td>mouse Bcl6</td>
<td>Sense</td>
<td>TGCTCAGGAGGCAGGCAGGCAG</td>
</tr>
<tr>
<td>mouse AcoT7</td>
<td>Sense</td>
<td>TGGTCCAGGAGGCCGCAGGCAG</td>
</tr>
<tr>
<td>mouse Actb</td>
<td>Sense</td>
<td>TGGTCCAGGAGGCCGCAGGCAG</td>
</tr>
<tr>
<td>mouse Actb_SouthernBlot</td>
<td>Sense</td>
<td>TGGTCCAGGAGGCCGCAGGCAG</td>
</tr>
<tr>
<td>mouse AID</td>
<td>Sense</td>
<td>TGGTCCAGGAGGCCGCAGGCAG</td>
</tr>
</tbody>
</table>
Supplementary Table 2 Matsumoto et al. Genes included in the chromosomal loci frequently deleted in AID-activated human gastric AGS cells.

<table>
<thead>
<tr>
<th>Deleted loci and genes</th>
<th>AID activation for 1 week</th>
<th>AID activation for 3 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chromosome 3</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3q25-28;</td>
<td>MLF1</td>
<td>MBNL1</td>
</tr>
<tr>
<td></td>
<td>GFM1</td>
<td>MLF1</td>
</tr>
<tr>
<td></td>
<td>RARRES1</td>
<td>GFM1</td>
</tr>
<tr>
<td></td>
<td>KCNMB2</td>
<td>RARRES1</td>
</tr>
<tr>
<td></td>
<td>WIG1</td>
<td>SCHIP1</td>
</tr>
<tr>
<td></td>
<td>PIK3CA</td>
<td>IMP-2</td>
</tr>
<tr>
<td></td>
<td>MFN1</td>
<td>ETV5</td>
</tr>
<tr>
<td></td>
<td>GNB4</td>
<td>DKGK</td>
</tr>
<tr>
<td></td>
<td>USP13</td>
<td>RFC4</td>
</tr>
<tr>
<td></td>
<td>PEX5L</td>
<td>SIA1</td>
</tr>
<tr>
<td></td>
<td>BCL6</td>
<td>MASP1</td>
</tr>
<tr>
<td></td>
<td>TP73L</td>
<td>IFRG28</td>
</tr>
<tr>
<td></td>
<td>LEPREL1</td>
<td>BCL6</td>
</tr>
<tr>
<td></td>
<td>CLDN1, 16</td>
<td>LPP</td>
</tr>
<tr>
<td></td>
<td>IL1R1P</td>
<td>TP73L</td>
</tr>
<tr>
<td></td>
<td>FGFR2</td>
<td>LEPREL1</td>
</tr>
<tr>
<td></td>
<td>HRASLS</td>
<td>IQCG</td>
</tr>
<tr>
<td></td>
<td>OPA1</td>
<td>LMLN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL1R1P</td>
</tr>
<tr>
<td><strong>Chromosome 9</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9p21-23;</td>
<td>NFIB</td>
<td>PTPRD</td>
</tr>
<tr>
<td></td>
<td>SH3GL2</td>
<td>MPDZ</td>
</tr>
<tr>
<td></td>
<td>MLLT3</td>
<td>NFIB</td>
</tr>
<tr>
<td></td>
<td>IFNB1, W1, A5, A2, A8, E1</td>
<td>ZDHHC21</td>
</tr>
<tr>
<td></td>
<td>MTAP</td>
<td>IFNB1, W1, A5, A2, A8, E1</td>
</tr>
<tr>
<td></td>
<td>PSIP1</td>
<td>CDKN2A</td>
</tr>
<tr>
<td></td>
<td>CDKN2B</td>
<td>CDKN2A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SH3GL2</td>
</tr>
</tbody>
</table>

3q25-28; 9p21-23;